TME Pharma's unique technology disrupts tumor protection mechanisms and inhibits tumor repair in the tumor microenvironment. Their lead compound, NOX-A12, has shown promising results in clinical trials for brain cancer. TME Pharma aims to improve treatment outcomes for patients with cancer by enhancing the effectiveness of current treatments, including immuno-oncology approaches and standard care. They have a collaboration agreement with Merck & Co. to study NOX-A12 combined with KEYTRUDA in pancreatic and colorectal cancer. TME Pharma's pipeline also includes NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.